AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00805454
Drug: OPC-34712
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose, 0.5 to 25 mg
Trial: NCT01839084
Drug: Xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: general anaesthesia with xenon 60% in oxygen (FiO2=0.4)
Trial: NCT01839084
Drug: Isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: general anesthesia with isoflurane 1.2% in 40% oxygen/medical air
Trial: NCT02616848
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02616848
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00482313
Drug: PR OROS Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
Trial: NCT00560274
Drug: Pegasys
RxNorm normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00560274
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As prescribed
Trial: NCT00560274
Drug: epoetin beta [NeoRecormon]
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 30,000 IU sc/week (starting dose)
Trial: NCT00095992
Drug: ispinesib
RxNorm normalized name: Ispinesib
DrugBank: Ispinesib (DB06188)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks
Trial: NCT02398656
Drug: Tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TNK will be administered as a single intravenous bolus over 1-2 minutes within 90 minutes of the CT scan.
Trial: NCT01928446
Drug: Lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
Trial: NCT03941405
Drug: Albumin treatment
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one dose per day of a 40g albumin g/l gram(s)/litre for 10 days. resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value \> 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period
Trial: NCT04158856
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg po every day
Trial: NCT04158856
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days
Trial: NCT01156571
Drug: cangrelor P2Y12 (platelet) inhibitor
DrugBank: Cangrelor (DB06441)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01156571
Drug: Clopidogrel - 300 or 600 mg (study arm)
RxNorm normalized name: clopidogrel 300 MG
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Over encapsulated tablets.
Trial: NCT01156571
Drug: Clopidogrel 600 mg post cangrelor
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: over-encapsulated clopidogrel (600 mg)
Trial: NCT03616834
Drug: Tomivosertib (eFT-508)
RxNorm normalized name: EFTRENONACOG ALFA
DrugBank: Tomivosertib (DB15219)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tomivosertib (eFT-508) is a novel, small-molecule investigational drug being developed by eFFECTOR Therapeutics, as an antitumor therapy that acts by selectively inhibiting mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase (MNK)1 and MNK 2.
Trial: NCT00444652
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of enoxaparin a few time
Trial: NCT00921128
Drug: Muscimol
RxNorm normalized name: Muscimol
DrugBank: Muscimol (DB12458)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00152360
Drug: Orlistat
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See Detailed Description.
Trial: NCT03285672
Drug: FP-101
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
DrugBank: Albutrepenonacog alfa (DB13884)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Dose 1
Trial: NCT01006460
Drug: Rhodiola rosea, L., Eleutherococcus senticosus, Schisandra chinensis
DrugBank: Eleuthero (DB14303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules twice a day
Trial: NCT01006460
Drug: Panax ginseng
RxNorm normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules twice a day
Trial: NCT00400738
Drug: Saquinavir, lopinavir, ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: arm 1 = LPV/RTV 400/100 mg BID + SQV 1000 mg BID arm 2 = LPV/RTV 400/100 mg BID + SQV 600 mg BID arm 3 = LPV/RTV 266/66 mg BID + SQV 1000 mg BID arm 4 = LPV/RTV 266/66 mg BID + SQV 600 mg BID
Trial: NCT03965767
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use
Trial: NCT04500730
Drug: Shaoyao Gancao Decoction Jiawei
RxNorm normalized name: Gancao (Glycyrrhiza Glabra)
DrugBank: Glycyrrhiza glabra (DB14312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study herb will be prescribed for 28 consecutive days. Study follow up will be offered every 7 days till 56th day after enrolment.~Daily leg cramps log will be filled in by each individual everyday from day 0 to day 56.
Trial: NCT01455558
Drug: Pletaal
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part 1: a single dose of the SR (200mg x 1 tablet, QD) and IR (100mg x 2 tablets, BID) formulation of cilostazol orally 7 days apart in a fasted state~Part 2: a single dose of the SR (200mg x 1 tablet, QD) formulation of cilostazol 7 days apart in a fasted and a fed state~Part 3: multiple doses of the two formulations for eight consecutive days 21 days apart
Trial: NCT02660411
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
Trial: NCT02660411
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
Trial: NCT00190970
Drug: Ruboxistaurin
RxNorm normalized name: RUBOXISTAURIN
DrugBank: Ruboxistaurin (DB11829)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00369122
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00001966
Drug: Mind-body therapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00333177
Drug: Risperidone, administered orally (Oral Ris)
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral risperidone at dosage judged optimal by treating psychiatrist
Trial: NCT00333177
Drug: Risperidone, administered via injection (RLAI)
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed
Trial: NCT02059902
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine infusion runs for a total of 24 hours
Trial: NCT00693849
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/day as a single dose, increased to max 20 mg/day
Trial: NCT00693849
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/day as a single dose, increased to max of 200 mg/day
Trial: NCT00693849
Drug: Venlafaxine-XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/day given once daily; increased to 150-225 mg/day
Trial: NCT00232089
Drug: Tegaserod
RxNorm normalized name: Tegaserod
DrugBank: Tegaserod (DB01079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03458975
Drug: Sonoporation
RxNorm normalized name: triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gaseous microbubbles (Sonovue) combinated with Ultrasounds
Trial: NCT00100178
Drug: Daclizumab (DZB)
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00100178
Drug: Placebo control for Daclizumab (DZB)
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: saline intravenous infusions
Trial: NCT00902135
Drug: Interferon beta-1b (Betaseron, BAY86-5046)
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder
Trial: NCT00902135
Drug: Interferon beta-1b (Betaseron, BAY86-5046)
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder
Trial: NCT00491764
Drug: SCH 56592
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
Trial: NCT00491764
Drug: SCH 56592
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
Trial: NCT00491764
Drug: SCH 56592
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
Trial: NCT00491764
Drug: SCH 56592
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
Trial: NCT00491764
Drug: Terbinafine
RxNorm normalized name: Terbinafine
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg QD for 12 weeks.
Trial: NCT00902135
Drug: Interferon beta-1b (Betaseron, BAY86-5046)
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1b (Betaferon)
Trial: NCT01691274
Drug: PF-04895162
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, 300 mg, single, 1 day
Trial: NCT01691274
Drug: PF-04895162
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, 300 mg, twice a day, 14 days
Trial: NCT01691274
Drug: PF-04895162
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, to be decided, twice a day, 14 days
Trial: NCT03064542
Drug: carbimazole (CMZ) or thiamazole (TMZ)
DrugBank: Carbimazole (DB00389)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMZ or TMZ will be used to treat the hyperthyroidism till the FT4/TSH is in normal range.
Trial: NCT02806232
Drug: Biltricide (racemate praziquantel) oral tablets
RxNorm normalized name: praziquantel Oral Tablet [Biltricide]
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biltricide (600 mg tablet) was administered to participants at a dose of 20 mg/kg in Part 1, Cohort 1 and at a dose of 40mg/kg in Part 1, Cohort 2.
Trial: NCT02806232
Drug: Racemate Praziquantel ODT
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Racemate Praziquantel (PZQ) (150) mg was administered at a dose of 40 mg/kg in Part 1, Cohort 3 and at a dose of 60 mg/kg in Part 1, Cohort 4.
Trial: NCT00709657
Drug: ranibizumab, bevacizumab or pegaptanib
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: measurements are performed one week before and after anti-VEGF intravitreal injection
Trial: NCT02806232
Drug: Levo Praziquantel ODT
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.
Trial: NCT01473043
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg twice daily \[BD\] daily dosing until progression or prohibitive toxicity Dose titration by 2 levels upwards (7mg and 10mg) and downwards (3mg and 2mg) allowed per protocol
Trial: NCT00497315
Drug: combination chemotherapy (pemetrexed + cisplatin)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 (q 3 weeks for 3 cycles)
Trial: NCT00648856
Drug: Sertraline Hydrochloride Tablets 100 mg
RxNorm normalized name: sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg, single dose fed
Trial: NCT00881673
Drug: Maxidex
RxNorm normalized name: Maxidex
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical ophthalmic
Trial: NCT01572259
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04317404
Drug: 40 mg Triamcinolone acetonide
RxNorm normalized name: triamcinolone acetonide 40 MG/ML
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unilateral knee steroid injection
Trial: NCT02371798
Drug: Gadopentetate dimeglumine
RxNorm normalized name: Gadopentetate Dimeglumine
DrugBank: Gadopentetic acid (DB00789)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV administration of 0.2 mmol/kg of Gd-DTPA
Trial: NCT00551122
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00551122
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00551122
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00551122
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03385096
Drug: Busulfan (BU)
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan was administered at 3.2 mg/kg/day on days -8 to -6.~-7 to -4.
Trial: NCT03385096
Drug: Etoposide (VP-16)
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide was administered at 10 mg/kg/day on days -3 to -2.~-3 to -2.
Trial: NCT03385096
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan was administered at 200mg/m2 on day -2.
Trial: NCT04558216
Drug: Vonoprazan
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 20 mg tablets administered orally
Trial: NCT04558216
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg (Two 300 mg capsules)
Trial: NCT01680887
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00079768
Drug: Alemtuzumab (Campath)
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04439149
Drug: PI3K-beta Inhibitor GSK2636771
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00004006
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004006
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004006
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01332331
Drug: Ambrisentan - low dose
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
Trial: NCT01332331
Drug: Ambrisentan - high dose
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
Trial: NCT04680130
Drug: C-11 PiB
RxNorm normalized name: C-11 PiB
DrugBank: Pittsburgh Compound B (DB15161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completing PET scan looking for amyloid protein
Trial: NCT04680130
Drug: AV1451 Tau
RxNorm normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completing PET scan looking for tau protein
Trial: NCT04680130
Drug: C-11 ER176
RxNorm normalized name: choline C-11
DrugBank: Choline C-11 (DB09563)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Completing PET scan looking for neuroinflammation
Trial: NCT01076231
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01076231
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04242173
Drug: Cemiplimab-Rwlc
RxNorm normalized name: cemiplimab-rwlc
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab-rwlc will be administered as a flat dose of 350 mg IV over approximately 30 minutes every 21 days (+/- 3 days)
Trial: NCT02792413
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive a subcutaneous injection of Denosumab every 6 months for the duration of the study. In addition, they will receive vitamin D and calcium (which is the normal treatment) for the duration of the study.
Trial: NCT02792413
Drug: NaCl (placebo)
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive a subcutaneous injection of NaCl every 6 months for the duration of the study. In addition, they will receive vitamin D and calcium (which is the normal treatment) for the duration of the study.
Trial: NCT03548714
Drug: PT150
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention 1 includes PT150 with alcohol consumption
Trial: NCT00682721
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gram daily x number of days active in the study
Trial: NCT00751218
Drug: desloratadine
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: desloratadine, 5mg oral tablets, once daily for 28 days
Trial: NCT00751218
Drug: cetirizine
RxNorm normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cetirizine, 10 mg capsules once daily for 28 days
Trial: NCT03428607
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300mg BID
Trial: NCT03678883
Drug: 9-ING-41
RxNorm normalized name: ING-1
DrugBank: ING-1 (DB05831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.
Trial: NCT03678883
Drug: Gemcitabine - 21 day cycle
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1250 mg/m2 as a 30-minute intravenous infusion on Days 1 and 8 of a 21-day cycle
Trial: NCT03678883
Drug: Lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lomustine 30 mg/m² orally as a single dose, weekly for twelve weeks.
Trial: NCT03678883
Drug: Carboplatin.
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 6 IV over 1 hour on Day 1 of a 21-day cycle.